Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
10.4046/trd.2004.57.3.257
- Author:
Tae Won JANG
1
;
Jung Pil PARK
;
Hee Kyoo KIM
;
Chul Ho OK
;
Tae Sig JEUNG
;
Maan Hong JUNG
Author Information
1. Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. jangtw@ns.kosinmed.or.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Locally advanced;
Concurrent chemoradiotherapy
- MeSH:
Brain;
Carcinoma, Non-Small-Cell Lung*;
Chemoradiotherapy;
Cisplatin;
Consensus;
Consolidation Chemotherapy;
Drug Therapy;
Esophagitis;
Follow-Up Studies;
Humans;
Neoplasm Metastasis;
Neutropenia;
Pneumonia;
Radiation Pneumonitis;
Radiotherapy*;
Recurrence;
Survival Rate;
Thorax
- From:Tuberculosis and Respiratory Diseases
2004;57(3):257-264
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: There are many combinations of treatment for locally advanced non-small cell lung cancer (NSCLC). Recent studies have showed the efficacy of concurrent chemoradiotherapy (CCRT) in NSCLC. At present, however, there is no consensus about the optimal dosages and timing of radiation and chemotherapeutic agents. The aims of study were to determine the feasibility, toxicity, response rate, and survival rate in locally advanced NSCLC patients treated with doxetaxel and cisplatin based CCRT. METHOD: Sixteen patients with unresectable stage III NSCLC were evaluated from May 2000 until September 2001. Induction chemoradiotherapy consisted of 3 cycles of docetaxel (75 mg/m2/IV on day 1) and cisplatin (60 mg/m2/IV on day 1) chemotherapy every 3 weeks and concomitant hyperfractionated chest irradiation (1.15 Gy/BID, total dose of 69 Gy) in 6 weeks. Patient who had complete or partial response, and stable disease were applied consolidation chemotherapy of docetaxel and cisplatin. RESULTS: All patients showed response to CCRT. Four patients achieved complete response (25%), partial responses in 12 patients (75%). The major common toxicities were grade III or more of neutropenia (87.3%), grade III esophagitis (68.8%), pneumonia (18.8%) and grade III radiation pneumonitis (12.5%). Thirteen patients were ceased during follow-up period. Median survival time was 19.9 months (95% CI; 4.3-39.7 months). The survival rates in one, two, and three years are 68.7%, 43.7%, and 29.1%, respectively. Local recurrence was found in 11 patients (66.8%), bone metastasis in 2, and brain metastasis in 1 patient. CONCLUSION: The response rate and survival time of CCRT with docetaxel/cisplatin in locally advanced NSCLC were encouraging, but treatment related toxicities were high. Further modification of therapy seems to be warranted.
